OBJECTIVES: To estimate the impact of amisulpride continued reimbursement in schizophrenia treatment on payer’s budget in Poland. METHODS: The analysis was performed in 5-year time horizon from the payer (National Health Fund, NHF) perspective and payer+patient perspective. Only costs of medicines were included. On the base of IMS Health Poland sale data for years 2005‑2010 linear regression was conducted to predict consumption and prevalence of antipsychotics in Poland. Cost data of medicines were obtained from Ministry of Health and medicine portals in case of lack of reimbursement. One-way sensitivity analysis were performed for the key input parameters. RESULTS: From the payer perspective, cost of amisulpride is approximately €7.13 million in 2010 and €9.15 million in 2014 and it represents from 4.62% in 2010 to 4.28% in 2014 of the total cost of schizophrenia treatment estimated at  approximately €154.22 million in 2010 and €213.87 million in 2014. From the payer+patient perspective, cost of amisulpride is approximately €7.26 million in 2010 and €9.32 million in 2014 and it represents from 4.01% in 2010 to 3.85% of the total cost of schizophrenia treatment estimated at approximately €181.11 million in 2010 and €241.81 million in 2014. Increase of NHF and patients expenses is related to an increase of antipsychotics sales over a span of the next five years caused by expanding awareness of schizophrenia and the importance of treatment. CONCLUSIONS: Our findings suggest that the cost of treatment with amisulpride are at a reasonable level and represent a small proportion of the total costs of schizophrenia treatment both from the payer perspective and common payer+patient perspective. The declining trend in the share of amisulpride cost in total cost of schizophrenia is noticeable. Amisulpride is an alternative therapeutic option of schizophrenia treatment in Poland and its reimbursement from public funds is justified.